Welcome to the CURE blog.

/Blog/

Melinta to highlight progress of Baxdela™

Melinta Therapeutics reports that there will be nine presentations on Melinta programs at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which is being held April 22-25, 2017 in Vienna, Austria. The presentations include six posters and e-posters describing the clinical experience with Baxdela™ (delafloxacin), an investigational anionic fluoroquinolone, including important insights into the treatment of challenging patient types such as those who have diabetes, renal impairment, or obesity. ​ more​

By |April 20th, 2017|News|0 Comments

CaroGen strengthens Board and Discovery Team

CaroGen Corp, a developer of immunotherapies for HBV as well as other infectious diseases and cancer, announced today additions to its Board of Directors and named two key senior executive level scientists to its immunotherapy discovery and development team. Bijan Almassian, Ph.D., CaroGen’s CEO, said, “The addition of these three impressive and experienced individuals, greatly  strengthens the CaroGen team and positions the company well with respect to executing on its immunotherapy plans”.​

By |April 20th, 2017|News|0 Comments

UConn TIP sees record growth in startups

The University of Connecticut, has announced record growth in 2016 for the University’s Technology Incubation Program (TIP). TIP was established in 2004 to accelerate the growth of technology-based startups with a strong connection to the University of Connecticut. TIP companies raised record investments in 2016. Last year TIP startups attracted a record $39.9 million in debt and equity to accelerate the growth of their operations. This is $15.5 million more than the previous record set in 2014. more​

By |April 20th, 2017|News|0 Comments

Yale spin-out Biohaven thrives on pharma misfits

On Friday Biohaven jumped out with a $100 million IPO filing, after undergoing a radical, low-key revamp of its pipeline focus, clearly aimed at offering investors a chance at a late-stage biotech eyeing near-term FDA applications. Now, according to the S-1, the New Haven-based biotech’s lead drug is a CGRP therapy for migraine grabbed from Bristol-Myers Squibb. Bristol-Myers Squibb had shelved the drug until Biohaven came along with a new plan to revive it in the clinic. more​

By |April 20th, 2017|News|0 Comments

How medical research boosts CT’s economy

Over the past decade, several large pharmaceutical companies have either closed their doors in Connecticut or cut hundreds of jobs from their local payrolls. These moves pose a threat to the state economy. For Connecticut to thrive in the future, say state political, academic and business leaders, more jobs are needed in groundbreaking biomedical research and a home-grown biotech industry. The 10-year-old Yale Stem Cell Center, which is within Yale School of Medicine, is an example of how this can be done. It has already created more than 200 jobs; involves more than 450 Yale faculty, post-docs and students; has [...]

By |April 20th, 2017|News|0 Comments

Bactana Animal Health completes funding round

Bactana Animal Health, a company developing natural products aimed at reducing the use of antibiotics and hormones in the world’s food supply through enhancement of the gut microbiota, has announced the closing of its first round of funding. Investors in the round included Connecticut Innovations; New York-based Sustainable Income Capital Management, LLC; and a number of private investors. The company says it will use the financing proceeds to complete additional studies using its FPS-4™ product platform, hire personnel, establish commercial manufacturing capabilities, and prepare for its initial global product launch. more

By |April 20th, 2017|News|0 Comments

Achillion initiates patient dosing in PNH study

Achillion Pharmaceuticals has initiated patient dosing in a Phase 2 open-label study of ACH-4471, Achillion's first orally-administered, small molecule factor D inhibitor, for patients with paroxysmal nocturnal hemoglobinuria (PNH). This proof of concept study will assess the efficacy, safety, and pharmacokinetics of ACH-4471 in untreated patients with PNH. "We are pleased to have begun this trial in PNH patients to evaluate ACH-4471, the first orally-administered factor D inhibitor to have demonstrated complement alternative pathway (AP) inhibition in humans, which represents a potentially novel and unique mechanistic approach to treating this life-threatening disease," commented Milind Deshpande, Ph.D., President and Chief Executive [...]

By |April 20th, 2017|News|0 Comments

Cara Therapeutics closes public stock offering

Cara Therapeutics, a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the closing of its underwritten public offering. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities, including the completion of the Phase 3 program for I.V. CR845 in uremic pruritus, two Phase 3 trials of I.V. CR845 in acute pain and a Phase 2b trial of oral CR845 in osteoarthritis pain, as well as for working capital and general corporate purposes.​ more

By |April 20th, 2017|News|0 Comments

Design For Research Breakthroughs

By Robert Skolozdra, AIA, LEED AP, Svigals + Partners Too many in the healthcare and technology sectors find out the hard way that laboratories are not all created equal. Lab-facility owners, entrepreneurs, and scientists all have experienced what it’s like to work in less-than-ideal conditions. To achieve inspired breakthroughs in science, research organizations demand more than just workbenches, bright lighting, and powerful vent hoods. These clients deserve better, and they should expect more, too. Learn more about what architects and designers at Svigals+Partners do to create effective research facilities. View full article and interview with Robert Skolozdra here >>

By |April 18th, 2017|Blog|0 Comments

FDA approves Purdue’s Symproic® tablets

Shionogi and Purdue Pharma have announced that the FDA has approved Symproic® (naldemedine) 0.2 mg tablets C-II as a once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Symproic is currently a Schedule II controlled substance because it is structurally related to naltrexone. Shionogi Inc. submitted a petition for the descheduling of Symproic, or removal of the controlled substance classification, to the U.S. Drug Enforcement Administration, which is currently under evaluation. Symproic will be jointly launched and commercialized in the U.S. with Purdue Pharma and is expected [...]

By |April 9th, 2017|News|0 Comments